Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
Treatment of chronic hepatitis B has shown a rapid development in the last years leading to a shift of treatment strategies from interferon to hepatitis B virus (HBV)-polymerase inhibitors. In particular, treatment with HBV-polymerase inhibitors has changed the indication on how to treat a patient and when to stop therapy. Long-term treatment with HBV-polymerase inhibitors may often be required, even if it raises the possibility of resistance and subsequent treatment failure. This review provides a strategy on how to manage HBV therapy with the currently available treatment options.